More stories

PT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping to Personalize Healthcare

In this episode, Joe Moore and Kyle Buller interview CEO & Co-founder of Nue Life, Juan Pablo Cappello, from his home in Miami during...

COMPASS Pathways granted fifth US patent for crystalline psilocybin

London, UK – 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based...

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved...

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics”, today announced it has...

HAVN Life Successfully Exports Psilocybin from its Jamaica Facility into Canada

The Company Signs Supply Agreement with Nectar Health Sciences Laboratory Division Inc. to provide naturally derived psilocybin for research and development of therapeutic products...

Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021

VANCOUVER, BC, Nov. 22, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments...

PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications

Intellectual Property Filing and Protection Remains a Top Priority OXFORD, Ohio and COCONUT CREEK, Fla., Nov. 19, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV:...

Psychedelic Bulletin: DEA Again Increases Psychedelics Production Quotas; MindMed Announces Microdosing Study; Shorter Trips?

In an early September bulletin we reported on the DEA’s proposal to significantly increase the production quota for research psilocybin for 2021. Then, in...

Numinus to Begin Trading on the OTC Under Symbol NUMIF

VANCOUVER, BC, Nov. 19, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments...

Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders

SAN DIEGO, Nov. 18, 2021 /PRNewswire/ — Tryp Therapeutics (CSE:TRYP;OTCQB:TRYPF) (“Tryp” or the “Company“), a pharmaceutical company focused on developing psilocybin-based compounds for diseases...

PTSF85 – Ahmad Doroudian, Ph.D. of BetterLife Pharma and Dr. Abid Nazeer of Wesana...

In this week's Solidarity Fridays episode, we’re featuring two shorter interviews, recorded in a media room at the Wonderland Miami conference last week: CEO...

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical...

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

CHICAGO and TORONTO, Nov. 19, 2021 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life...

Most popular